Overview

Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS

Status:
Completed
Trial end date:
2017-11-27
Target enrollment:
Participant gender:
Summary
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with DSXS .
Phase:
Phase 2
Details
Lead Sponsor:
Taro Pharmaceuticals USA